Cancer-based anti-cancer treatment, not genetically biomarkers, was promptly approved by the Department of Food and Drug Administration.

For Vitactvi this week, a new method of developing cancer cancer drugs for the larotrectinib brand – the "tissue agent" – is cancerous, not characteristic of a single organ, such as colon or breast.

Vitakvi, developed by Bayer and Lokso's Oncology, is designed to treat solid organisms from the syndrome of Toxic Synthesis. Mutations are rare – treatment is not cheap.

Only cancer testing is thousands of, and treatment prices can reach hundreds of thousands of dollars. It is not clear how much the patient pays, but Bayer is not in need of drugs anymore.

"This mutation does not have cancer that is commonly referred to as an anal sex secretion carcinoma, cellular or mixed-mesoblastic nephroma and infantile fibrosarcoma," the statement said.

More: Cancer continued with oncological diseases. New therapies give him hope

More: High price in preclinical medicine increases the bitter choice of oncology patients

Treatment is followed by mutation in DNA and the numbers are vigorous. Seventy-five per cent of the respondents answered that 73 per cent of the responses lasted at least six months. Approximately 40 percent lasted for one year or more, the FDA reported.

FDA Commissioner Scott Gottlieb has named the approval as "an important step in the treatment of cancer-based cancer genetics."

The fixing reveals the achievements in the use of genetic biomarkers aimed at the development of medicinal preparations aimed at providing the drug more closely. He said drug development would not be possible ten years ago.

Vitakvi's immediate approval allows FDA patients to take medication in substantial cases to meet their medical needs by using clinical trial data that presupposes clinical practice. Subsequent clinical trials at work, FDA reports.

The FDA has initiated a review of the drug and a thorough therapy. Vitakvi received symptoms of "Orthopedic Disease", which stimulates the promotion and promotion of rare diseases.

"We can make sure that the right patients receive timely treatment," says Gothlieb.

Read or share this story: